The assessment of pathological response to neoadjuvant chemotherapy in muscle- invasive bladder cancer patients with DCE- MRI and DWI: a systematic review and meta-analysis

被引:1
|
作者
Zong, Ruilong [1 ]
Ma, Xijuan [1 ]
Shi, Yibing [1 ]
Geng, Li [2 ]
机构
[1] Xuzhou Cent Hosp, Dept Radiol, Xuzhou 221000, Peoples R China
[2] Xuzhou Med Univ, Affiliated Hosp, Dept Radiol, Xuzhou, Peoples R China
来源
BRITISH JOURNAL OF RADIOLOGY | 2023年 / 96卷 / 1150期
关键词
CONTRAST-ENHANCED MRI; URINARY-BLADDER; TUMOR HETEROGENEITY; CELL CARCINOMA; ANGIOGENESIS; DIFFUSIVITY; PREDICTION; CISPLATIN;
D O I
10.1259/bjr.20230239
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: The purpose of this meta-analysis was to determine the value of dynamic contrast-enhanced- MRI (DCE- MRI) and diffusion-weighted imaging (DWI) in evaluating the pathological response of muscle invasive bladder cancer (MIBC) to neoadjuvant chemotherapy (NAC), and further indirectly compare the diagnostic performance of DCE- MRI and DWI. Methods: Literatures associated to DCE- MRI and DWI in the evaluation of pathological response of MIBC to NAC were searched from PubMed, Cochrane Library, web of science, and EMBASE databases. The quality assessment of diagnostic accuracy studies 2 tool was used to assess the quality of studies. Pooled sensitivity (SE), specificity (SP), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the receiver operating characteristic curves (AUC) with their 95% confidence intervals (CIs) were calculated to evaluate the diagnostic performance of DCE- MRI and DWI in predicting the pathological response to NAC in patients with MIBC. Results: There were 11 studies involved, 6 of which only underwent DCE-MRI examination, 4 of which only underwent DWI examination, and 1 of which underwent both DCE-MRI and DWI examination. The pooled SE, SP, PLR, NLR, DOR of DCE- MRI were 0.88 (95% CI: 0.78- 0.93), 0.88 (95% CI: 0.67-0.96), 7.4 (95% CI: 2.3-24.2), 0.14 (95% CI: 0.07-0.27), and 53 (95% CI: 10-288), respectively. The pooled SE, SP, PLR, NLR, DOR of DWI were 0.83 (95% CI: 0.75-0.88), 0.88 (95% CI: 0.81-0.93), 7.1 (95% CI: 4.3-11.7), 0.20 (95% CI: 0.14-0.28), and 36 (95% CI:18-73), respectively. The AUCs of SROC curve for DCE- MRI and DWI were 0.93 (95% CI: 0.91-0.95) and 0.92 (95% CI: 0.89-0.94), respectively. There were no significant differences between DWI and DCE- MRI for SE, SP, and AUC. Conclusion: This meta-analysis demonstrated high diagnostic performance of both DCE- MRI and DWI in predicting the pathological response to NAC in MIBC. DWI might be a potential substitute for DCE- MRI, with no significant difference in diagnostic performance between the two. However, caution should be taken when applying our results, as our results were based on indirect comparison. Advances in knowledge: No previous studies have comprehensively analysed the value of DCE- MRI and DWI in evaluating the pathological response to NAC in MIBC. According to the current study, both DCE- MRI and DWI yielded high diagnostic performance, with the AUCs of 0.93 and 0.92, respectively. Indirect comparison no significant difference in the diagnostic performan-ceof DCE- MRI and DWI.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
    Kronstedt, Shane
    Saffati, Gal
    Hinojosa-Gonzalez, David E.
    Doppalapudi, Sai Krishnaraya
    Boyle, Joseph
    Chua, Kevin
    Jang, Thomas L.
    Cacciamani, Giovanni E.
    Ghodoussipour, Saum
    UROLOGY, 2024, 194 : 289 - 294
  • [22] Perioperative Intravesical Chemotherapy in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
    Ahern, Michael R.
    Owusu, Richmond A.
    Anderson, Mark R.
    Rampersaud, Edward N.
    Inman, Brant A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (04): : 477 - 484
  • [23] MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis
    Janssen, L. M.
    den Dekker, B. M.
    Gilhuijs, K. G. A.
    van Diest, P. J.
    van der Wall, E.
    Elias, S. G.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [24] MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis
    L. M. Janssen
    B. M. den Dekker
    K. G. A. Gilhuijs
    P. J. van Diest
    E. van der Wall
    S. G. Elias
    npj Breast Cancer, 8
  • [25] A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer
    Meeks, Joshua J.
    Bellmunt, Joaquim
    Bochner, Bernard H.
    Clarke, Noel W.
    Daneshmand, Siamak
    Galsky, Matthew D.
    Hahn, Noah M.
    Lerner, Seth P.
    Mason, Malcolm
    Powles, Thomas
    Sternberg, Cora N.
    Sonpavde, Guru
    EUROPEAN UROLOGY, 2012, 62 (03) : 523 - 533
  • [26] A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.
    Ikram, Waleed
    Naqvi, Syed Arsalan Ahmed
    Fatima, Ezza
    Siddiqi, Rabbia
    Islam, Mahnoor
    Asghar, Noureen
    Khakwani, Kaneez Zahra Rubab
    Khan, Ahsan Masood
    Xu, Wenxin
    Hussain, Syed A.
    Sonpavde, Guru P.
    Bryce, Alan Haruo
    Bin Riaz, Irbaz
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [27] Adjuvant chemotherapy for muscle invasive bladder cancer: A systematic review and meta-analysis.
    Cruz, MRS
    Sasse, E
    Sasse, A
    Clark, L
    Clark, O
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 436S - 436S
  • [28] The role of 18F-FDG PET/MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis
    Ghanikolahloo, Milad
    Taher, Hayder Jasim
    Abdullah, Ayoob Dinar
    Anar, Mahsa Asadi
    Tayebi, Ali
    Rahimi, Rahil
    Olamaeian, Faranak
    Rahimikashkooli, Nima
    Kargar, Nima
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [29] Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
    Seah, Jo-An
    Leibowitz-Amit, Raya
    Atenafu, Eshetu G.
    Alimohamed, Nimira
    Knox, Jennifer J.
    Joshua, Anthony M.
    Sridhar, Srikala S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : E229 - E233
  • [30] BLADDER PRESERVATION THERAPY FOR THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Inamoto, Teruo
    Ibuki, Naokazu
    Komura, Kazumasa
    Minami, Koichiro
    Takai, Tomoaki
    Uchimoto, Taizo
    Saito, Kenkichi
    Tanda, Naoki
    Tsujino, Takuya
    Matsunaga, Tomohisa
    Yoshikawa, Yuki
    Hirano, Hajime
    Nomi, Hayahito
    Juri, Hiroshi
    Yamamoto, Kiyohito
    Yamamoto, Kazuhiro
    Narumi, Yoshifumi
    Azuma, Haruhito
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1044 - E1044